Martha-Maria Krankenhaus Halle-Doelau gGmbH
- Address
- lock Available on a paid plan
Analytical, Diagnostic & Therapeutic Techniques
The neurology department at Martha-Maria Krankenhaus Halle-Doelau gGmbH employs advanced diagnostic imaging and biomarker analysis to support precision oncology trials, especially in lung and bladder cancers.
- Development of imaging biomarkers for early response assessment
- Validation of liquid biopsy assays for EGFR and KRAS mutations
- Integration of surgical navigation tools in minimally invasive procedures
- Evaluation of novel electrophysiological monitoring devices
With 15 investigators overseeing 37 active studies, the site leverages cutting‑edge technology to improve trial accuracy and patient safety.
Cardiovascular Diseases
Although the primary focus is neurology, the hospital contributes to cardiovascular research through collaborative diagnostic programs and risk‑factor monitoring in oncology patients.
- Assessment of cardiac safety in immunotherapy regimens
- Monitoring of vascular events during targeted lung cancer treatment
- Integration of echocardiography in trial safety protocols
The multidisciplinary environment ensures comprehensive evaluation of heart health alongside cancer therapies.
Hemic and Lymphatic Diseases
The site explores the impact of cancer therapies on the blood and lymphatic systems, focusing on hematologic safety and immune modulation.
- Investigation of neutropenia rates with combined chemotherapy and immunotherapy
- Study of lymphocyte dynamics in patients receiving checkpoint inhibitors
- Evaluation of thrombosis risk in advanced lung cancer cohorts
These efforts help refine supportive care guidelines for patients undergoing intensive oncologic regimens.
Male Urogenital Diseases
Clinical research includes trials targeting urothelial carcinoma and prostate malignancies, aiming to improve outcomes with novel immunotherapies.
- Combination of PD‑L1 inhibitors with chemotherapy in bladder cancer
- Evaluation of adjuvant immunotherapy after cystectomy
- Biomarker‑driven studies in metastatic prostate cancer
The department collaborates with urology specialists to ensure integrated patient management.
Neoplasms
A major portion of the trial portfolio addresses solid tumours, especially various forms of lung cancer, renal cell carcinoma, and bladder cancer.
- Testing EGFR‑targeted agents in early‑stage non‑small cell lung cancer
- Assessing KRAS G12C inhibitors across multiple lung cancer cohorts
- Maintenance therapies for renal cell carcinoma post‑surgery
- Neoadjuvant immunotherapy strategies for muscle‑invasive bladder cancer
The site’s strong oncology focus enables rapid enrollment and comprehensive follow‑up for patients with advanced malignancies.
Nervous System Diseases
The neurology unit leads trials in multiple sclerosis and inflammatory neuropathies, seeking new disease‑modifying treatments.
- Evaluation of novel antibodies for secondary progressive MS
- Safety and efficacy of targeted therapies in chronic inflammatory demyelinating polyneuropathy
- Biomarker studies to predict relapse in autoimmune neuropathies
These studies aim to reduce disability progression and improve quality of life for patients with chronic neurological disorders.
Respiratory Tract Diseases
Research extends to non‑oncologic pulmonary conditions, including severe asthma and bronchiectasis, focusing on biologic therapies and exacerbation reduction.
- Comparison of long‑acting anti‑IL‑5 agents in eosinophilic asthma
- Evaluation of novel inhaled treatments for bronchiectasis flare‑ups
- Assessment of quality‑of‑life outcomes in chronic respiratory disease trials
The department’s expertise in pulmonary function testing supports rigorous assessment of respiratory endpoints.
Environment and Public Health
The hospital participates in studies examining the influence of environmental factors on disease incidence, with a focus on air quality and its impact on respiratory and oncologic health.
- Correlation of particulate matter exposure with lung cancer progression
- Population‑based surveillance of asthma exacerbations linked to pollution spikes
- Public health initiatives to improve indoor air standards in clinical settings
Findings aim to inform preventive strategies and policy recommendations at regional and national levels.
Behavioral Disciplines and Activities
Complementary research addresses patient‑centered outcomes, including psychological support and lifestyle interventions for individuals undergoing intensive cancer therapy.
- Impact of counseling on treatment adherence in lung cancer trials
- Exercise programs to mitigate fatigue during chemotherapy
- Cognitive assessments for patients with brain metastases
Integrating behavioral health services enhances overall trial experience and may improve clinical results.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 83 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 83 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG7trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Martha-Maria Krankenhaus Halle-Doelau gGmbH
lock Showing 1 of 40 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study Comparing Sigvotatug Vedotin and Docetaxel in Adults with Previously Treated Non-Small Cell Lung Cancer | Seagen Inc. | Phase III | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 83 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 11 | Unknown | 2018-04-04 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.